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INTRODUCTION
Cationic polymers, both of natural and synthetic origin, have
been intensively studied due to their immense therapeutical
potential including delivery of gene which is probably their best
known biomedical application (1). Synthetic polycations are
synthesized often with desired molecular weight, they can be
easily modified and do not show batch-to-batch variation, a
typical disadvantage of natural polymers. The synthetic
polycations, which are the most intensively studied in biomedical
applications, especially in drug delivery, tissue engineering and
gene delivery, are polyethyleneimines (PEIs) (2) poly(L-lysine)
(PLL) (3), poly(amino-co--esters) (PAEs) (4, 5) and
poly(dimethylaminoethylmethacrylates) (PDMAEMAs) (6, 7).
However, they are often toxic, show poor hemocompatibility, and
low biodegradability (8, 9).
On the other hand, the cationic polymers of natural origin are
actually limited to proteins with chitosan being a unique polymer
as the only natural cationic polysaccharide. Chitosan is a random
copolymer of N-acetyl-D-glucosamine and D-glucosamine (10).
In nature it occurs in small amounts in the cell walls of several
genera of mushrooms e.g., Mucor, Rhizopus, and Absidia (11,
12). However, on a synthetic scale it is obtained by deacetylation
of chitin, the main component of the crustacean shells (13, 14)
being regarding the validity of the importance second (after
cellulose) substance in the biosphere. The process of chitin
deacetylation may be carried out to different degree leading to
chitosans of various degrees of deacetylation (DD). DD and the
molecular weight are two important characteristics of chitosan
that determine its physicochemical properties, solubility in
particular. Its structure, physicochemical properties and
biological functions are determined by the presence of three
types of functional reactive groups, i.e., hydroxyl, amino, and
acetamido groups. Chitosan is soluble only in acidic solutions.
Its solubility is higher for chitosans with higher DDs and lower
molecular weight (15). Chitosan has found many commercial
applications in cosmetics (16), food industry (17), agriculture
(18), environmental protection (19), wastewater management
(20), and chemical industry (13).
UNMODIFIED CHITOSANS
Chitosan has many beneficial biomedical properties such as
biocompatibility, biodegradability, and nontoxicity. Biological
activity of chitosan is closely related to its solubility and thus to
both molecular weight and DD. Decreasing molecular weight
increases absorption of chitosan after oral administration in mice
(21) and rats (22). When absorbed, low-molecular-weight chitosan
was found to be distributed to various of tested organs, i.e., liver,
kidney, spleen, thymus, heart, and lung, and easily metabolized.
Chitosan decreases absorption of lipids in the intestine by
binding bile acids and fatty acids (23). Therefore, the
polysaccharide is a well-known dietary weight-reducing
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Chitosan is biocompatible polymer obtained from chitin, the building component of the crustacean shells. In this paper
we make an attempt to review the current state of knowledge on some biological effects of chitosan in comparison with
those of cationically modified chitosan, N-(2-hydroxypropyl)-3-trimethylammonium chitosan chloride (HTCC) that was
recently synthetized by us by covalent attachment of glycidyltrimethylammonium chloride (GTMAC). Biological
effects of HTCC and non-modified polymer are very similar. However, HTCC shows some unique beneficial properties
which have not been found in its non-modified counterpart. One such example is that HTCC has the ability to bind
heparin at physiological pH. HTCC having the degree of substitution almost 63.6% is easily absorbed within 1 hour after
oral administration as found in C57BL/6j mice using FITC-labeled polymer. HTCC is distributed to lung, heart, and
kidneys. HTCC stimulates and enhances blood platelet aggregation and decreases erythrocyte deformability (RBC).
Moreover, HTCC seems to decrease both plasma total cholesterol level and LDL-cholesterol level in apoE-knockout
mice fed with a diet containing HTCC. HTCC possibly down-regulates the HMG-CoAR mRNA level after 24 hour
incubation with HepG2 cells in vitro.
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supplement. Oral chitosan lowers plasma cholesterol (24, 25)
without adverse effects. The mechanism of hypocholesterolemic
action of chitosan is still unclear. However, it has been suggested
that chitosan acts by inhibiting the absorption of cholesterol and
bile acids (23). Due to stronger electrostatic attraction between
this cationic polysaccharide and anionic substances like bile
acids and fatty acids, chitosan with higher DD (about 90%) and
molecular weight shows higher fat-binding capacity (12). On the
other hand, its cholesterol lowering effect does not show a clear
dependence on the above features (12). Its hypocholesterolemic
potency seems to be related to inhibition of progression of
atherosclerosis (26).
One of the most important properties of chitosan is its
inherent antimicrobial effect, that was first recognized more than
40 years ago (27), against many Gram-positive and Gram-
negative bacteria, yeasts, and fungi (28, 29).
Furthermore, chitosan is one of the most intensively studied
and safe component of drug delivery systems (30) prepared in
different forms, e.g. as a hydrogel (31), nanoparticles (32-35),
microparticles (28), and films (36); and administered by various
routes, including topical (33) e.g. general mucosal (37), nasal
(31), intraocular (38) and oral. Chitosan-based oral drug delivery
systems may be quite advanced and include oral insulin
administration (32), colon drug delivery (39), gastroretentive
floating drug systems (40), or gene delivery (41, 42).
Other pharmacological properties of chitosan are: antitumor
(43), immuno-enhancing (44, 45), wound healing (46), and
antidiabetic (47, 48). In biotechnology chitosan is employed in
tissue engineering (49, 50) and as a cell culture support (51, 52).
Chitosan reveals immuno-stimulating effect because of its
impact on the body’s immunological response to inflammation
(45, 53). This polysaccharide increases production of interleukin
1 (IL-1), platelet-delivered growth factor, transforming growth
factor b1 and phagocytosis of macrophages. Chitosan enhances
also phagocytosis of polymorphonuclear leukocytes (PMN) and
production of leukotriene B4 and osteopontin. These effects are
crucial for healing of large open wounds as found in animals.
Chitosan polymers induce fibroblasts to release interleukin-8
(IL-8) involved in proliferation and migration of vascular
endothelial cells and fibroblasts (45, 53). Chitosan when
delivered intranasally enhances systemic and local immune
responses to tetanus toxoid, influenza pertussis and diphtheria
vaccines (45, 54-57). Similar effects were observed after oral
gene-delivery with chitosan-DNA nanoparticles in animal
studies (45, 58, 59). Another studies showed that chitosan might
limit an immunosuppression (45, 59). It was observed that after
chitosan subcutaneous implantation in dogs the number of white
blood cells was increased (45, 60).
CATIONIC CHITOSAN DERIVATIVES
The poor solubility of chitosan in water significantly
constrains its possible applications. These limitations can be at
least partially overcome by its cationic modification with
ammonium groups which are ionized irrespective of the pH value.
Biological activity of the cationically modified chitosan
overlaps significantly with that of the native chitosan and
includes antibacterial (60) and antifungal (61) properties,
enhancing adsorption of hydrophilic drugs through mucous
membranes (62-64) improving proliferation of human
periodontal ligament cells (HPDLC) (65) and inhibition the
proliferation of cancer cells (66).
However, some properties are unique to cationically-
modified chitosan. Studies on one of these type of polymers,
including our recently performed studies, are as follows:
Antiheparin properties of cationically-modified chitosan
As previously described by us cationic modification
(quaternization) of chitosan was conducted by covalent
attachment of glycidyltrimethylammonium chloride (GTMAC)
(67).
Two polymers of N-(2-hydroxypropyl)-3-trimethylammonium
chitosan chloride with degree of substitution (DS) 63.6% and
90.5%, referred to as HTCC1 and HTCC2 respectively, were
obtained. The modified chitosans showed very good solubility in
water at physiological pH. In PBS buffer at pH=7.4 the zeta
potential of HTCC1 and HTCC2 was found to be 13.28±1.21 and
24.2±0.83 respectively, indicating that these polymers may have a
tendency to the formation of polycation-polyanion complexes.
Indeed, it was shown that HTCC polymers form complexes with
heparin - a strongly anionic polysaccharide anticoagulant -
accompanied by the inhibition of anticoagulative activity of both
unfractionated heparin (UFH) and low-molecular-weight heparin
(LMWH) (61). Moreover, heparin activity could not only be
blocked by HTCC but also removed from the solution in vitro in
the form of microspheres crosslinked with genipin, a naturally-
occurring compound obtained from Gardenia fruit (68).
Absorption and distribution of HTCC in mice after oral
administration
HTCC absorption we have studied in C57BL/6j mice after
oral administration of this polymer previously labeled with
fluorescein isothiocyanate (FITC) (unpublished data). High
level of FITC fluorescence that has been found in serum
1 hour after oral administration indicates that HTCC is easily
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Fig. 1. Substitution reaction of chitosan with GTMAC. Ch, chitosan; GTMAC, glycidyltrimethylammonium chloride; HTCC, N-(2-
hydroxypropyl)-3-trimethylammonium chitosan chloride.
absorbed from GI tract. HTCC was distributed mainly to lung
and heart and particularly high HTCC concentration was
found in kidney. Twenty four hours after oral administration
HTCC was completely eliminated both from serum and the
studied organs. However, there are studies indicating that
some of unmodified high-molecular weight chitosan samples
(HCS, Mw=760,000 Da) would gradually precipitate at the
lower intestine and would be hardly absorbed if their
molecules were not degraded into soluble ones (21). In mice
plasma level of HCS half an hour after oral administration was
very low and this level was negligible later (1 hour time point
or even at 4 hour time point after administration). In kidney
the highest concentration of HCS was found after 2 hours and
then at 4th hour was significantly decreased. A large quantity
of HSC was observed in feces when HSC was used as dietary
fiber supplements (21).
HTCC stimulates and enhances platelet aggregation
Chitosan with moderately high molecular weight (Mw=50,000
Da) and high degree of deacetylation (DD>90%) enhances platelet
aggregation and adhesion in rabbits, increases expression of
platelet glycoprotein GPIIb/IIIa complex on platelet membrane
and significantly increases platelet intracellular Ca2+ (69). We
have found that HTCC with DS of 63.6% essentially stimulates
human platelet aggregation in vitro and this phenomenon is dose-
dependent (unpublished data). This phenomenon occurs in the
absence of collagen and it is in contrast to platelet aggregation
accompanying the bleeding from wounded vessels. The above
results suggest that cationically modified chitosan may be an
effective hemostatic agent but its hemostatic mechanism seems to
be independent on the classical coagulation cascade (70). It also is
well established that chitosan deprived cationic modification
accelerate wound healing (71, 72). Unmodified chitosan inhibits
the diffuse capillary bleeding in brain tissue (73) and the lingual
bleeding in heparinized rabbits (74).
The effect on red blood cell deformability
It is well established that atherosclerosis and hyperlipidemia
are related to microcirculatory disturbances and they are
accompanied by decrease of red blood cell (RBC) deformability.
However, in rabbits with hypercholesterolemia induced by the
hen’s egg enriched diet the deformability of RBC was found to be
increased (75). It was speculated that this could be a result of the
changes in the mean corpuscular volume, viscosity of erythrocyte
cytoplasm, and oxidative/antioxidative balance. We have found
that HTCC with DS of 63.6% causes significant decrease of RBC
deformability in human blood in vitro (unpublished data).
Significant decrease of human RBC deformability was also found
to be induced by chitooligosaccharide with Mw =50,000 Da,
however its potency was much lower than HTCC.
The effect on lipid metabolism and hypercholesterolemia in the
apolipoprotein E-deficient mouse model of atherosclerosis
To study the effect of HTCC on lipid and cholesterol
metabolism we have used the apolipoprotein E-knockout mice
model of atherosclerosis (76, 77). The apoE-knockout
homozygous mutant mice have total plasma cholesterol level
five times higher than that of normal animals while triglyceride
levels are 68% higher than in normal litter mates. The high
density lipoprotein (HDL) cholesterol levels reach only 45% of
the normal level. Gene-targeted apoE-knockout mouse model
proved to be very useful in the development of the inflammatory
theory of atherosclerosis (78). In addition, process of
atherogenesis seems to be affected by a gender of ApoE(–/–)
mice. This effect is connected with markedly elevated
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Fig. 2. Molecular simulation of a chitosan-cholesterol complex obtained by Gaussian 98 software. The simulation displays the ability
to create a specific sites of electrostatic bonds between chitosan chains and cholesterol molecules. It is believed that cholesterol do not
cause great perturbation in the shape of the chitosan molecule. The interaction between chitosan and cholesterol was found between
several charged sizes of the chitosan molecules (–NH3+) and the OH group of cholesterol. Distance between two sites of interaction of
cholesterol with chitosan has been measured and the value is 9 A° .
production of thromboxane A2 (TXA2) and reduced prostacyclin
(prostaglandin I2, PGI2) production in female ApoE(–/–) mice
(79). To restrain of atherosclerosis progress some compounds
were studied in mice model successfully, e.g., antileukotriene
drugs (80), AVE 0991 - angiotensin(1-7) receptor agonist (81)
and doxycycline (82). Chitooligosaccharides have angiotensin-I-
converting enzyme (ACE) inhibitory activity (13, 83).
In apoE-deficient mice fed for 20 weeks on a diet containing
5% w/w of chitosan (DD=78%) blood cholesterol level was
significantly decreased to 64% of that in the control animals (i.e. on
a diet without chitosan). Examination of the area of aortic plaque
showed a potent inhibition of atherogenesis in the whole aorta
(about 42%) as well as in the aortic arch (50%) as compared to
control mice (26). Moreover, we found that apoE-knockout mice
fed for 16 weeks with a diet containing 200 mg of HTCC (with DS
of 63.6%) per 1 kg of body weight, had total plasma cholesterol
and LDL level lower by about 15% and 32%, respectively, as
compared to the control (unpublished data). Fig. 2 contains an
explanation of the possible mechanism of binding of cholesterol to
chitosan according to molecular simulation of complexes of
chitosan-cholesterol obtained with the Gaussian 98 software (84).
It is supposed that cationically modified chitosan (HTCC)
may form pseudomicelles with cholesterol. In these structures
cholesterol is inside pseudomicelle and more hydrophobic
fragments of chitosan (main hydrocarbon chain) are immersed in
hydrophobic centrum of cholesterol. Hydrophilic fragments of
chitosan molecule through its electrostatic charges become
oriented towards peripheries of pseudomicelles and this way the
structures turn to more stabilized form. Stability of these
microstructures in water environment possibly makes removal of
cholesterol from the body much easier than in the form of
agglutinated drops. Similar effect occurs in the case of fatty acids
and their salts where pseudomicelles are additionally stabilized by
electrostatic interactions between carboxyl groups of acids and
cationic hydrophilic domains in chitosan molecule. In addition, it
seems that these pseudomicellar structures may be stabilized by
hydrogen bonds between number of OH groups present in
chitosan and nucleophile atoms in cholesterol structure.
The effect of chitosan on the activity of 3-hydroxy-3-
methylglutaryl coenzyme-A reductase (HMG-CoAR) - a hepatic
enzyme involved in metabolism of lipoproteins, has previously
been studied in rats (85). In rats fed a chitosan-sterol diet
(DD=92%) the activity of HMG-CoAR increased more than in
those fed with a sterol diet but less than in rats fed with a normal
diet. Further studies with rats fed with chitosan using semi-
quantitative RT-PCR showed that chitosan could downregulate
the HMG-CoAR mRNA level (13). We found that also HTCC
significantly down-regulates the HMG-CoAR mRNA level after
24 hour incubation with HepG2 cells in vitro (real-time PCR
results). This effect was not observed after incubation with
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Location Native chitosan  HTCC 
Blood  - enhances platelet aggregation and adhesion in rabbits  
- decreases human red blood cells deformability  
- increases expression of platelet glycoprotein GPIIb/IIIa complex 
on platelet membrane  
- increases platelet intracellular Ca2+
- forms complexes with heparin, a strongly anionic 
polysaccharide anticoagulant  
- stimulates and enhances platelet aggregation  
- decreases human erythrocyte deformability  
- hemostatic mechanism may be independent of the 
classical coagulation cascade  
- zeta potential of HTCC polymers may show a 
tendency to the formation  of polycation-polyanion 
complexes  
Absorption and 
distribution 
(Pharmacokinetics) 
- reduced molecular weight increases absorption of chitosan after 
oral administration in mice and rats  
- when absorbed is distributed to liver, kidney, spleen, thymus, 
heart, and lung, then  easily metabolized  
- FITC-labeled is easily absorbed within 1h after 
oral administration in mice  
- distributed to lung, heart, and kidneys  
Bioavailability 
(Pharmacokinetics) 
- at pH 5 solubility is only infinitesimal so bioavailability is minimal   - higher bioavailability than unmodified chitosan 
due to its better solubility in physiological 
conditions   
- well soluble at blood pH, so may stay in blood for 
longer time and may affect the level of fatty acids 
and cholesterol  
Absorption in GI 
truck 
- interacts strongly with cholesterol in the stomach leading to 
slowing of cholesterol absorption  
- due to its solubility in wide range of pH it should 
probably be well absorbed not only from the 
stomach  
Lipid metabolism - lowers plasma cholesterol level after oral administration justifying 
the idea that it may inhibit progression of atheroscleoris  
- conception that it may inhibit progression of atherosclerosis  
- decreases absorption of lipids in the intestine by binding bile acids 
and fatty acids  
- due to stronger electrostatic attraction between its cationic part of 
molecule and anionic substances, like bile acids and fatty acids it 
shows higher fat-binding capacity. Cholesterol lowering effect does 
not seem to be dependent on this phenomenon  
- the interaction between chitosan and cholesterol was found to be 
located between a charged particles of the chitosan (-NH3+) and the 
OH group of cholesterol  
- in rats fed with a chitosan/sterol diet the activity of HMG-CoAR is 
increased more than in those fed with a sterol diet but less than fed 
with a normal diet  
- chitosan administered orally may down-regulate the HMG-CoAR 
mRNA level in rats 
- decreases both plasma total cholesterol level and 
LDL- cholesterol level in apoE-knockout mice when 
they fed with it in daily diet  
- it may form pseudomicelles with cholesterol. The 
stability of pseudomicelles in water environment 
makes cholesterol easier to be removed. Similar 
phenomenon occurs with fatty acids and their salts 
when pseudomicelles are stabilized by electrostatic 
interactions  
- down-regulates the HMG-CoAR mRNA level after 
24 hour incubation with HepG2 cells in vitro. This 
effect is not observed after incubation with 
chitooligosaccharides deprived cationic 
modification  
Skin - accelerates wound healing  ? 
Table 1. Comparison of various biological characteristics of the native chitosan with HTCC.
chitooligosaccharide (Mw=5,000 Da) deprived cationic
modification (unpublished data).
Is cationically modified chitosan (HTCC) more efficient in
regulating lipid metabolism than native chitosan?
It is believed that HTCC has higher bioavailability than
unmodified chitosan and this due to its better solubility in
physiological conditions. Native chitosan at pH 5 is soluble only
infinitesimally so its bioavailability is minimal. On the other
hand, at pH in the stomach unmodified chitosan becomes soluble
and in such conditions it may easily be absorbed to blood. But pH
of blood is 7.4, so concentration of the chitosan in blood is
expected to be rather low and then chitosan may be subject to
rapid uptake by organs. Furthermore, beneficial function of
chitosan is binding of fatty acids and cholesterol in blood.
Unmodified chitosan interacts with cholesterol in the stomach so
effectively that practically it doesn’t let cholesterol to be absorbed
from digestive tract. In contrast to unmodified chitosan, HTCC,
due to its solubility at wide range of pH, has a big chance to be
absorbed not only from the stomach. On the other hand, HTCC is
well soluble at pH of blood, so it may stay in blood for longer
time and therefore to influence the blood level of fatty acids and
cholesterol very effectively. To sum up, HTCC having the
characteristics of a chitosan it is just a more effective (Table 1).
In summary, HTCC is a well-absorbed cationic chitosan
derivative that displays important biological activities including
recently found effect on lipid metabolism. Some of its activities,
e.g. binding of heparin or cholesterol lowering effect, appear to
be quite unique. Although HTCC in principle mimics the actions
of unmodified chitosan but it is doing this with clearly better
effectiveness and this may prove useful from the therapeutic
point of view.
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